Wall Street brokerages expect Biodel Inc. (NASDAQ:ALBO) to announce earnings of ($0.83) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Biodel’s earnings. The lowest EPS estimate is ($0.87) and the highest is ($0.79). Biodel reported earnings of ($0.90) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 7.8%. The firm is expected to report its next earnings report on Thursday, August 10th.

On average, analysts expect that Biodel will report full-year earnings of ($3.77) per share for the current financial year, with EPS estimates ranging from ($4.29) to ($3.32). For the next financial year, analysts expect that the company will post earnings of ($3.39) per share, with EPS estimates ranging from ($4.03) to ($2.97). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Biodel.

Biodel (NASDAQ:ALBO) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.10) by $0.04.

A number of brokerages have recently weighed in on ALBO. Wedbush began coverage on Biodel in a research report on Friday, June 30th. They set an “outperform” rating for the company. Needham & Company LLC began coverage on Biodel in a research report on Tuesday, July 18th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Zacks Investment Research upgraded Biodel from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a research report on Tuesday, July 11th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $31.50.

A hedge fund recently raised its stake in Biodel stock. Renaissance Technologies LLC boosted its stake in Biodel Inc. (NASDAQ:ALBO) by 0.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 149,632 shares of the biopharmaceutical company’s stock after buying an additional 794 shares during the period. Renaissance Technologies LLC’s holdings in Biodel were worth $3,591,000 as of its most recent SEC filing. 12.35% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This report was posted by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/13/brokerages-anticipate-biodel-inc-albo-will-post-earnings-of-0-83-per-share.html.

Biodel (NASDAQ ALBO) opened at 22.51 on Friday. The stock’s market capitalization is $141.63 million. The stock has a 50 day moving average price of $23.73 and a 200 day moving average price of $22.09. Biodel has a 12 month low of $10.80 and a 12 month high of $37.69.

Biodel Company Profile

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Get a free copy of the Zacks research report on Biodel (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Biodel (NASDAQ:ALBO)

Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.